ABSTRACT: No disease-modifying osteoarthritis (OA) drugs are available to prevent posttraumatic osteoarthritis (PTOA). Mitochondria (MT) mediate the pathogenesis of many degenerative diseases, and recent evidence indicates that MT dysfunction is a peracute (within minutes to hours) response of cartilage to mechanical injury. The goal of this study was to investigate cardiolipin-targeted mitoprotection as a new strategy to prevent chondrocyte death and cartilage degeneration after injury. Cartilage was harvested from bovine knee joints and subjected to a single, rapid impact injury (24.0 AE1.4 MPa, 53.8 AE 5.3 GPa/s). Explants were then treated with a mitoprotective peptide, SS-31 (1mM), immediately post-impact, or at 1, 6, or 12 h after injury, and then cultured for up to 7 days. Chondrocyte viability and apoptosis were quantified in situ using confocal microscopy. Cell membrane damage (lactate dehydrogenase activity) and cartilage matrix degradation (glycosaminoglycan loss) were quantified in cartilage-conditioned media. SS-31 treatment at all time points after impact resulted in chondrocyte viability similar to that of un-injured controls. This effect was sustained for up to a week in culture. Further, SS-31 prevented impact-induced chondrocyte apoptosis, cell membrane damage, and cartilage matrix degeneration. Clinical Significance: This study is the first investigation of cardiolipin-targeted mitoprotective therapy in cartilage. These results suggest that even when treatment is delayed by up to 12 h after injury, mitoprotection may be a useful strategy in the prevention of PTOA. ß
Currently, no disease-modifying osteoarthritis (OA) drugs are available to prevent or slow the progression of posttraumatic OA (PTOA). 1, 2 Evidence suggests that therapies targeting acute biological responses after articular injury may provide benefit by preventing ongoing chondrocyte death and progressive extracellular matrix degradation. 3, 4 Mitochondrial dysfunction mediates the pathogenesis of many degenerative diseases, including syndromes that develop secondary to traumatic injury. 5, 6 Some of the earliest known pathologic changes in OA, including oxidative stress and chondrocyte apoptosis are mediated by mitochondria (MT). 3, 4, [7] [8] [9] [10] [11] Mitochondrial dysfunction is well documented in the later stages of OA. 7, 8 For example, chondrocytes isolated from patients with end-stage OA exhibit MT respiratory dysfunction, with lower spare respiratory capacity and higher proton leak compared to healthy chondrocytes, as well as down-regulation of the MTspecific antioxidant superoxide dismutase-2. 12 OA is also associated with decreased numbers of MT, and deficiencies in the metabolic biosensors AMPK and SIRT1 that regulate MT biogenesis. 13 MT-associated disease pathways are linked to chronic stages of the disease, including decreased synthesis of collagen and proteoglycans and pathologic calcification of cartilage. 7, 8, [14] [15] [16] [17] Furthermore, mutations of mtDNA affecting MT function are associated with an increased incidence of knee OA. 18 Several in vivo models have assessed MT function in the sub-acute to early chronic stages after cartilage insult. Chondrocyte respiratory function was impaired 4 weeks after surgical destabilization of the medial meniscus (DMM) in rabbits. 19 Similarly, in a mouse DMM model, MT superoxide overproduction and SOD 2 down regulation occurred in knee cartilage two weeks postoperatively. 20 Chondrocytes isolated from SOD-2 deficient cartilage displayed MT depolarization, decreased MT respiratory function, and swollen MT with disrupted cristae structure. Furthermore, proteoglycan content was decreased and extracellular matrix metabolism was impaired by down regulation of anabolic genes and upregulation of catabolic genes, including MMP-13. 20 Increasing experimental evidence also indicates that MT dysfunction plays a central role in the initiation and very early pathogenesis of PTOA, although the mechanisms are not fully characterized. Evidence from ex vivo chondral injury models suggests that in cartilage, as in other tissues, MT may act as intracellular mechanotransducers via strain-activated release of reactive oxygen species (ROS). [21] [22] [23] [24] This theory is supported by the findings that chondrocyte compression distorts the MT network, MT-derived reactive oxygen species induced chondrocyte death, and chondrocyte cytoskeleton dissolution prevents elevated ROS and cell death in injured cartilage. 22, [24] [25] [26] Increases in intracellular calcium lead to MT depolarization within 3-6 h of cartilage injury, activation of the caspase cascade and chondrocyte apoptosis. 27 Recently, MT respiratory dysfunction was identified in the acute phase (within 2 h) after cartilage impact injury. 28 Evidence for the role of MT dysfunction in OA has led to interest in developing clinical therapies that target MT-associated pathways. To date, investigational therapies have generally targeted downstream consequences of MT dysfunction, namely redox imbalance and activation of the caspase cascade, 4 however no specific mitoprotective therapies have been evaluated as potential disease modifying OA drugs. In contrast to drugs that are simply targeted to the MT, or participate in MT-associated disease pathways, mitoprotective drugs can be defined as agents that directly protect MT structure and function, and restore MT plasticity.
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The Szeto-Schiller peptides (SS-31) represent a novel class of mitoprotective agents that repair mitochondrial cristae structure, restore mitochondrial function, improve cellular bioenergetics, and prevent cell death. [29] [30] [31] SS-31 (Elamipretide; Stealth Peptides, Newton, MA) exerts these effects through its specific interaction with cardiolipin, a phospholipid that is uniquely expressed on the inner mitochondrial membrane. 32 Cardiolipin promotes folding of cristae membranes and is important for the formation of respiratory supercomplexes that facilitate electron transfer and ATP synthesis. However, cardiolipin is highly susceptible to oxidative damage, and cardiolipin peroxidation results in loss of cristae membranes, a decline in ATP production, increase in ROS production, release of cytochrome c and initiation of apoptosis. 33 By interacting with cardiolipin, SS-31 promotes cristae curvature, improves mitochondrial coupling, ATP production, reduces ROS production, inhibits cardiolipin peroxidation, and prevents apoptosis. 33, 34 SS-31 is currently in multiple Phase II and III trials for both rare and common MT diseases, demonstrating its safe use in humans. 35, 36 SS-31 has not previously been studied in cartilage, therefore the goals of this study were to test if SS-31 could prevent impactinduced chondrocyte death and cartilage degeneration, and if mitoprotective efficacy would be affected by the time of administration after impact.
METHODS

Tissue Harvest
Full thickness cartilage explants were harvested from the medial femoral condyles of healthy bovids (n ¼ 8 animals, 1-3 days of age) within 48 h of euthanasia using an 8 mm biopsy punch, as previously described. 28 Specimens were rinsed in phosphate-buffered saline (PBS), trimmed to a uniform thickness of 3 mm from the articular surface (leaving the articular surface intact) using a custom jig, and placed in media (phenol free DMEM containing 1% FBS, HEPES 0.025 ml/ml, penicillin 100 U/ml, streptomycin 100 U/ml, and 2.5 mM glucose). Experiments were approved by the University Institutional Animal Care and Use Committee.
Rapid Impact Injury Model
Explants were subjected to injury using a validated rapidimpact model, or served as un-impacted controls, as previously described. 28, 37 Briefly, explants were positioned in a well containing PBS under the plane-ended tip of a springloaded impacting device, with the articular surface facing up (Fig. 1) . 38, 39 The impactor was used to deliver a single, rapid cycle of unconfined axial compression (24.0 AE 1.4 MPa peak stress; 53.8 AE5.3 GPa/s peak stress rate). Impact force was measured at 50 kHz by a load cell (PCBPiezotronics, Depew, NY) attached to the impactor tip. Voltage from the load cell was recorded with a custom LabVIEW program (NI, Austin TX). The impact magnitude was adjusted by setting the deflection of the impactor's internal spring and mechanical parameters for each impact were calculated as previously described. 37 
Study Design
Following injury, explants were kept moist and cut perpendicular to the articular surface into two hemicylinders using a custom jig, then placed into a 24-well plate containing 1.5 ml of media. Cartilage hemicylinders were randomly assigned to one of 10 treatment groups (n ¼ 6/group, Fig. 1 ). Injured (I) and uninjured control (C) explants in the nontreated (NT) groups (INT, CNT) were placed into wells containing only media. Other explants were treated with SS-31 (1 mM) at time zero (IT 0 , CT 0 ), 1 h (IT 1 , CT 1 ), 6 h (IT 6 , CT 6 ), or 12 h (IT 12 , CT 12 ) after impact (Fig. 1 ). Explants were maintained under standard tissue culture conditions (37˚C, 21% O 2, and 5% CO 2 ) for up to 7 days. After 24 h, culture media were replaced with media containing no SS-31, then replenished every other day for the duration of the experiment. Medium was sampled (200 ml/well) at 1, 6, 12, and 24 h, and at 3, 5, and 7 days after impact, and stored at À80˚C until biochemical assays were performed. After imaging was complete, cartilage explants were lyophilized and weighed.
Chondrocyte Viability
Chondrocyte viability was assessed in situ using a live/dead imaging assay. At 1 or 7 days post-impact, cartilage was rinsed and placed in PBS containing calcein AM (2 mM) and ethidium homodimer (1 mM) for 30 min at 37˚C, to stain live and dead cells, respectively. Explants were then imaged on a Leica SP5 confocal microscope. Digital images were acquired in two channel sequential scans (green; 488/498-544 and red; 514/563-663 nm excitation/emission, respectively) using a modified 3D scanning protocol; A minimum of three z-stacks (ten images, 512 Â 512 pixel/387.5 Â 387.5 mm, spaced 10 mm apart in the z plane) per explant were acquired at 10Â magnification. All imaging parameters were optimized during preliminary studies, then the same settings were used throughout the study.
The number of live, dead, and total cells in each image was quantified using custom ImageJ macros (Mac OS X version 10.2, Wayen Rasband, U.S. National Institutes of Health, Bethesda, MD) as previously described. 28 Briefly, Each image was thresholded based on mean pixel intensity of that image, then individual particles were identified and 2148 DELCO ET AL.
counted based on particle size. For each image, the % of dead cells was calculated as the number of dead cells counted in the red channel divided by the total number of cells (live þ dead) counted in both channels. The final reported values for cell death are the mean of a minimum of three z-stacks obtained for each explant.
Apoptosis (Activated Caspase Staining) At 1 or 7 days post-impact, cartilage was placed in PBS containing CellEvent Caspase 3/7 (Molecular Probes, Eugene, OR) to detect activated caspase activity. Explants were imaged on a Leica SP5 confocal microscope and digital z-stacked images were acquired as described above in two channel sequential scans; 488/498-544 excitation/emission to image apoptotic cells and reflectance to highlight collagen in the extracellular matrix. The number of caspase-positive cells per field were counted using a custom ImageJ macro and expressed as the number of apoptotic cells per mm 2 .
Cell Membrane Damage
Imaging studies were validated with biochemical assays performed on cartilage-conditioned media. As a measure of cell membrane damage, the release of lactate dehydrogenase (LDH) from cartilage explants was quantified using a commercial kit (Sigma-Aldrich, St. Louis, MO). NADH absorbance was measured at 450 nm in 5-min intervals by a spectrophotometric microplate reader (Tecan Safire; M€ annedorf, Switzerland). LDH activity was calculated following subtraction of background media values and expressed as milliunits of LDH per ml of cartilage conditioned media.
Cartilage Matrix Degeneration
To determine if SS-31 could inhibit cartilage matrix degradation after impact injury, loss of glycosaminoglycan (GAG) into media was determined by routine 1,9-dimethylmethylene blue dye binding (DMMB) assay, as previously described. 40 Briefly, media samples were digested using papain (Sigma Aldrich) 0.25 mg/ml at 65˚C for 4 h. A standard curve was prepared using chondroitin-4-sulfate (Sigma Aldrich). Equal volumes of sample and DMMB dye (Sigma Aldrich) were mixed in a 96-well plate. Total GAG content was read fluorometrically, and expressed as the total GAG released into cartilage conditioned media over the culture period per mg dry weight of cartilage.
Distribution and Localization of SS-31 in Cartilage
A concern with any chondrocyte-targeted drug is the question of diffusion through the avascular, highly charged extracellular matrix of cartilage. To investigate the distribution of SS-31, 6 mm diameter cartilage explants were harvested as described above and incubated in PBS with biotinylated SS-31 (SPI-72; Biotin-D-Arg-Dmt-Lys-Phe-NH2) 2 nM and Mitotracker Green (200 nM; Molecular Probes) for 1 h at 25˚C. Cartilage explants were then bisected, and hemicylinders were fixed for 24 h in 10% neutral buffered formalin. After fixation, bisected halves were exposed to streptavadin-AlexaFluor633 (5 ug/ml; Molecular Probes) for 4 h, rinsed for 15 min in PBS, then imaged using confocal microscopy as previously described. 32 To confirm that SS-31 can localize to chondrocyte mitochondria in vivo, aladanated SS-31 (SPI-70; D-Arg-Dmt-Lys-ALD-NH2; 30mls of 10uM) 41 was injected into the femeropatellar joints of two adult horses (age unknown) immediately following euthanasia. Horses were euthanized for reasons other than this study. The limbs were manipulated through a passive range of motion intermittently for 60 min, then cartilage explants were harvested from the medial femoral condyles, tibial plateau and patellofemoral grooves and placed in PBS containing tetramethylrhodamine methyl ester perchlorate (TMRM;10 nM, Molecular Probes) for 40 minutes, then rinsed in PBS. Cartilage was imaged using a Zeiss LSM880 confocal/multiphoton microscope (2 photon excitation at 720 nm/510-540 nm excitation and 561 nm emission/569-611 nm excitation) and colocalization analysis was performed using ZEN Imaging software (Carl Zeiss AG, Oberkochen, Germany).
Effect of SS-31 in Adult Tissue
To investigate the effects of mitoprotection in adult tissue, and to validate findings obtained in immature cartilage, impact experiments were performed on cartilage harvested from the medial femoral condyles of adult bovine stifle joints (n ¼ 2 animals, >18 months of age), and chondrocyte viability was assessed as described above.
Statistical Analysis
Data were analyzed using a linear mixed effects model, with a random effect of trial/animal and fixed effects of injury (I, C), treatment time (T 0 , T 1 , T 6 , T 12, NT), and response time (day 1, day 7), including all interactions. Comparisons between groups were performed using Tukey's HSD method. Residual analyses were performed to ensure the assumptions of normality and homogeneous variance were met. Differences were considered statistically significant at p 0.05. Statistical analyses were performed using JMP Pro Version 11.0 (SAS Inc.) software.
RESULTS
SS Peptides Diffuse Throughout Cartilage and Localize to Chondrocyte Mitochondria
After incubation of explants with biotinylated SS peptide for 1 hour, fluorescent imaging revealed mitochondrial probe (MitoTracker Green) and the streptavidinconjugated fluorophore (AlexaFluor633) in chondrocytes throughout the depth of the cartilage (Fig. 2) . This confirms that SS-31 readily diffuses through the extracellular matrix. After incubation of cartilage with fluorescent SS-31 ([ald]SS-31) 32 and a mitochondrial probe (TMRM), multiphoton imaging of individual chondrocytes and colocalization analysis revealed localization of SS-31 to chondrocyte mitochondria.
Mitoprotection Prevents Impact-Induced Chondrocyte Death and Apoptosis
To test if mitoprotection could prevent impact-induced chondrocyte death, cartilage was injured and immediately treated with SS-31, then chondrocyte viability was assessed on days 1 and 7 post-impact by live/dead staining. Cartilage injury resulted in a 2.5-fold increase in cell death (Fig. 3) . SS-31 treatment prevented impact-induced chondrocyte death at 1 day post-injury (p < 0.001), resulting in chondrocyte viability similar to un-injured controls. When chondrocyte viability was assessed 7 days post-injury, findings were similar (Fig. 3) . This indicates that although SS-31 was withdrawn from culture media after 24 h, its cytoprotective effects were sustained for a week in culture. Cell death was not significantly different on days 1 and 7 in uninjured, non-treated (CNT) explants (p ¼ 0.98), indicating that chondrocyte viability was maintained for the 7-day culture period. SS-31 had no effect on chondrocyte viability in uninjured explants. SS-31 also provided cytoprotection in adult cartilage, decreasing the amount of impact induced chondrocyte death by half (Fig. S1) .
Treatment with SS-31 also prevented impact-induced caspase 3/7 activation, a marker of apoptosis. Imaging of explants 1 day after injury revealed an increase in the number of caspase-positive cells throughout the depth of the cartilage (Fig. 4) . SS-31 prevented impact-induced apoptosis on days 1 (p ¼ 0.007) and 7 (p ¼ 0.04) after injury. There was a trend toward fewer apoptotic cells on day 7 than day 1 in all groups, most notably in injured, treated explants but this difference did not reach significance (p ¼ 0.07).
Mitoprotection Prevents Cell Membrane Damage and
Cartilage GAG Loss Cumulative cell membrane damage, quantified by LDH activity in cartilage conditioned media for 7 days following injury, was twofold lower after injury in treated versus untreated cartilage (p ¼ 0.0005, Fig. 5a ). SS-31 also had a protective effect against cell membrane damage in uninjured controls; uninjured, treated samples had a lower cumulative LDH than untreated controls (p ¼ 0.05).
SS-31 treatment protected against cartilage matrix degradation after injury. GAG loss into cartilage conditioned media was significantly (p ¼ 0.03) increased in injured, untreated (INT) explants (4.6 s.d. 1.0 mg GAG/ml media) starting on day 3 post-injury compared to uninjured controls (3.7 s.d. 0.8 mg GAG/ml media). Cumulative GAG loss over the 7 day culture period was $30% greater in injured, untreated explants (INT) compared to uninjured controls (Fig. 5b) , indicating impact-induced cartilage matrix degeneration. SS-31 prevented impact-induced GAG 
The Effect of Treatment Time on Mitoprotective Efficacy
To investigate the therapeutic window for mitoprotection after acute cartilage injury, explants were injured and treatment was delayed for up to 12 h. SS-31 initiated at 0, 1, or 6 h after impact significantly reduced cell death in injured groups versus the INT group (IT 0 ; p ¼ 0.0007, IT 1 ; p < 0.0001, IT 6 ; p ¼ 0.0003) resulting in chondrocyte viability similar to uninjured controls (CNT; p ¼ 0.16). This represents a 37-48% reduction in impact-induced chondrocyte death in IT 0 , IT 1 , and IT 6 groups (Fig. 6a) . The cytoprotective effect of SS-31 was less pronounced when treatment was delayed 12 h after injury. Cell death in the IT 12 group was significantly greater than the treated control group (CT 0 ), and not different than the injured, untreated group (INT).
The efficacy of SS-31 to provide structural protection after cartilage injury was similarly time-sensitive (Fig. 6b) . Injured groups treated up to 6 h post-impact (IT 0 , IT 1 , and IT 6 ) had GAG loss similar to unimpacted groups (CNT and CT 0 ), but when treatment was delayed 12 h, GAG loss was not different than injured, untreated samples (INT).
DISCUSSION
The aim of this work was to investigate mitoprotection as a new strategy to prevent posttraumatic osteoarthritis, and our data indicate that SS-31 prevents injury-induced chondrocyte death, caspase activation, cell membrane damage, and matrix degradation. The concept of targeting MT-associated disease pathways in the treatment and prevention of OA is not novel; several groups have targeted events downstream of MT dysfunction [42] [43] [44] [45] [46] (Fig. 7) . Despite promising preclinical results, traditional antioxidants such as N-acetyl cysteine and vitamin C have not provided clinical benefit in OA patients. 1, 2, 4 Caspase inhibitors, including synthetic inhibitors of caspase 3 and 9, prevent MT-mediated cell death by preventing activation of the caspase cascade and apoptosis in vitro, but have not progressed to clinical testing. 4, 46 Ideally, to prevent the initiation and progression of PTOA, interventions would target upstream events and preserve cartilage homeostasis. 3 However, until recently no specific mitoprotective therapies (i.e. agents that directly protect MT structure and function) were available.
Most modern drugs target single proteins in signaling pathways involved in specific disease processes. However, MT are complex, multi-compartment organelles that rely on a vast network of proteins and lipids to carry out and regulate ATP synthesis. Therefore, previous attempts to identify a single molecular target to improve MT function have been unrewarding. 29 SS peptides offer a new therapeutic strategy; by specifically protecting cardiolipin, these novel peptides preserve MT structure and promote MT function. Cardiolipin is a phospholipid dimer expressed exclusively on the inner MT membrane, with small acidic head groups and four diverging hydrophobic acyl chain tails resulting a conical shape. 47 Incorporation of cardiolipin into the lipid bilayer causes the inner MT membrane to bend, forming the characteristic folded structure of MT cristae. 47 Cardiolipin rafts organize electron transport chain proteins into supercomplexes, shortening the distance between redox partners and increasing efficiency of electron transfer. This optimizes ATP production, and reduces ROS generation. Cardiolipin also anchors cytochrome C to the inner MT membrane, where it executes the rate-limiting step of oxidative phosphorylation. During MT stress, cardiolipin is easily oxidized, which distorts cristae structure. This leads to decreased ATP production, increased electron leak in the electron transport chain with increased ROS generation, and dissociation of cytochrome C from the inner MT membrane, setting the stage for apoptosis. 20, 33 Therefore, by protecting cardiolipin, SS-31 can optimize the function of all integral proteins on the inner mitochondrial membrane to promote oxidative phosphorylation, reduce excess ROS production, and prevent MT-induced apoptosis and autophagy. 48 Mitotoxicity is a major concern with any MTtargeted compound, and many candidate drugs are not effectively delivered to MT. Recently, several MT-targeted antioxidants have been developed. In order to target drugs to MT, lipophilic compounds are often conjugated to cationic moieties such as TPPþ (triphenylphosphonium ion), which enter the MT matrix due to the potential gradient across the inner MT membrane, which can lead to MT depolarization. Unlike these TPP þ-conjugated antioxidants, SS-31 does not enter the MT matrix, and has no pro-oxidant activity. 29 It is clinically important to note that extensive toxicology studies have shown SS-31 to be safe for in vivo use; SS-31 has no effect on normal cells, and no cytotoxic or mitotoxic effects have been observed in studies at concentrations exceeding 100uM ex vivo, up to 50 mg/kg in vivo animal models, and up to 0.25 mg kg À1 h À1 over 4 h in human safety studies.
30
A concern with any chondrocyte-targeted osteoarthritic drug is the question of diffusion through the avascular, highly charged cartilage matrix. Owing to their unique chemical structure, SS peptides are highly water soluble, while able to freely diffuse (translocate) across lipid membranes by transcellular transport. 49 This results in a volume of distribution similar to blood volume, and no accumulation in lipid, further limiting concerns for toxicity. Our ex vivo and in vivo imaging studies confirm that SS-31 distributes throughout the thickness of cartilage and localizes to chondrocyte mitochondria after intra-articular injection.
To investigate the possible clinical relevance of SS-31 as a "point-of-injury" therapy in the acute stages following cartilage trauma, a time course experiment was performed. Our findings suggest that even when treatment was delayed by 12 h after injury, mitoprotective therapy may be a useful strategy to prevent ongoing chondrocyte death and cartilage degeneration. Previous in vitro work indicates that impact-induced cell death peaks at 2-3 h following injury. 28, 50 However, MT-mediated cell death evolves over a slower time scale than necrotic cell death (days versus hours, respectively). [50] [51] [52] [53] [54] Time course studies of progressive apoptosis in cartilage have been investigated by several methods, and indicate chondrocyte apoptosis may be initiated around 6 h and sustained for up to 7 days post-injury. [51] [52] [53] [54] In a recent in vitro study, chondrocyte MT respiratory dysfunction occurred within 2 h of cartilage impact. 28 These findings suggest that following injury, a subset of chondrocytes experience acute MT-dysfunction, but remain viable for an indeterminate amount of time. SS-31 may act to stabilize this The absolute time course presented in this study should not be over-interpreted, however. It is important to note that SS-31 was withdrawn at 24 h in all treatment groups. Therefore, it is possible that the inferior mitoprotective efficacy observed in the IT 12 group may be due to shorter drug exposure, and equal protection may be observed if treatment is continued for similar lengths of time. Furthermore, this ex vivo model utilizes a single-impact followed by static tissue culture. In vivo, MT dysfunction likely continues following acute cartilage trauma. For example, recent work suggests that articular injury inhibits cartilage lubrication mechanisms, and that increased frictional coefficients due to inadequate lubrication are associated with MT depolarization and chondrocyte apoptosis. 55, 56 Taken together, this suggests that in a clinical scenario, the effective window for mitoprotective intervention after joint injury is likely not limited to hours, but may continue throughout the course of ongoing cartilage degeneration. Recent evidence also indicates that beyond protecting MT from damage, SS-31 promotes MT repair after injury and can restore MT function. Once repaired, mitochondria were protected for at least 6 months after termination of drug treatment. Preclinical and clinical studies would be required to determine the most effective dosing regimens in patients after joint trauma.
Our findings indicate that, in addition to providing cytoprotection, SS-31 can prevent impact-induced cartilage matrix degradation. GAG release into cartilageconditioned media is a well-established indicator of cartilage injury. In the present study, GAG loss was significantly increased in injury groups versus controls starting on day 3 post-injury. Conversely, previous studies have documented immediate injury-induced GAG loss; that is, between days 1 and 3 post-injury, but not after day 3. 57 The reason for this difference is likely related to the distinct loading regimens employed between studies. Immediate and nonsustained GAG loss observed in other models may be due to mechanical disruption of matrix rather than cell-mediated enzymatic degradation. 57 A lag time in injury-induced GAG release in the present study, and inhibition of GAG release by SS-31 suggests that mitoprotection prevents injury-induced cartilage matrix degradation. Although the mechanism for cartilage matrix protection by SS-31 was not directly investigated in the present study, the current findings are consistent with known mechanisms in other cell types. When oxidized, cardiolipin can translocate to the outer MT membrane and trigger multiple cell stress responses, including inflammasome activation and induction of IL-1b. 58 Recent evidence supports a role for MT damage in inflammasome activation in OA, and treatment with SS-31 one month after injury reversed upregulation of the inflammatory markers IL-1b, IL-18, and TNF-a in a model of chronic inflammation and fibrosis. [59] [60] [61] Furthermore, previous work has demonstrated that MT-derived reactive oxygen species are important regulators of matrix degrading enzymes, matrix metalloproteinases (MMPs). 16, [62] [63] [64] In human cartilage explants, MT respiratory chain dysfunction led to upregulation of MMP-1, -3 and -13 and loss of proteoglycan staining. 16 Mitochondrial redox imbalance also increased MMP-1 and 13 levels, and a MT-targeted superoxide scavenger reduced MMP levels in primary chondrocytes. 63 A limitation of the current study is that experiments were performed at 21% O 2 concentration, which is considered relative hyperoxia for normal cartilage. 65 There is disagreement in the literature regarding the effect of O 2 concentration on chondrocyte metabolism, and most studies have investigated this question in isolated chondrocytes. [66] [67] [68] [69] One group assessed the level of oxidative phosphorylation in freshly harvested 1 mm cubes of cartilage from young mature bovids. They found that at O 2 concentrations between 5 and 21%, oxygen consumption rate (OCR) was relatively constant at $10 nM/10 6 cells/h, 67 similar to OCR values measured in recent work using the same techniques described in the present study. 28 OCR in cultured chondrocytes was also found to be independent of O 2 and glucose concentration in short term (48 hour) culture. 66 Therefore, the finding of mitoprotection at 24 h post-injury is unlikely to be affected by oxygen concentration. Furthermore, although 21% O 2 is considered physiologic for normal cartilage, it is unclear what oxygen concentration chondrocytes experience after joint trauma. The current study was conducted at 21% O 2 to be consistent with recent work linking cartilage trauma to mitochondrial dysfunction in the same experimental system. 28 Additional studies are warranted to investigate the effect of mitoprotection at various oxygen concentrations in situ.
In summary, this is the first study to investigate targeted mitoprotection in cartilage. Our findings demonstrate that SS-31 prevents chondrocyte death and cartilage matrix degradation, even when treatment is delayed up to 6 h after cartilage injury. The unique properties of this class of drugs confer their ability to provide structural protection to MT cristae by specifically interacting with cardiolipin, thereby preventing MT dysfunction. 30, 32 Our data suggest that SS-31 has the potential to be an effective disease modifying osteoarthritis drug, and preclinical testing is warranted.
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